SCHEMBL7429693

SCHEMBL7429693

O=C(O)Cc1csc2ccc(Br)cc12

nearest known ligand 0.68

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.68
NFE2L2 Q16236 1/20 0.68
CYP2A6 P11509 3/20 0.61
CA2 P00918 1/20 0.54
HDAC10 Q969S8 1/20 0.53
HDAC11 Q96DB2 1/20 0.53
HDAC8 Q9BY41 1/20 0.53
HDAC6 Q9UBN7 1/20 0.53
MAPT P10636 4/20 0.48
UTS2R Q9UKP6 1/20 0.47
PPARD Q03181 2/20 0.40
PPARA Q07869 2/20 0.40
PPARG P37231 1/20 0.40
TP53 P04637 1/20 0.39
SLC22A12 Q96S37 1/20 0.39
MTNR1A P48039 1/20 0.39
MTNR1B P49286 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28563290 0.86 CYP2A6 (0.64) KEAP1NFE2L2CYP2A6CA2HDAC10
SCHEMBL8253324 0.84 CYP2A6 (0.58) KEAP1NFE2L2CYP2A6CA2HDAC10
SCHEMBL8173706 0.82 KEAP1 (0.48) KEAP1NFE2L2CYP2A6CA2HDAC10
SCHEMBL30469746 0.82 CYP2A6 (0.55) KEAP1NFE2L2CYP2A6CA2HDAC10
SCHEMBL8246357 0.82 CYP2A6 (0.55) KEAP1NFE2L2CYP2A6CA2HDAC10
SCHEMBL15897090 0.82 CYP2A6 (0.55) KEAP1NFE2L2CYP2A6CA2HDAC10
SCHEMBL8255701 0.81 CYP2A6 (0.58) KEAP1NFE2L2CYP2A6CA2HDAC10
SCHEMBL22499949 0.81 KEAP1 (0.68) KEAP1NFE2L2CA2MAPTPPARD
SCHEMBL1520041 0.81 KEAP1 (1.00) KEAP1NFE2L2CYP2A6CA2MAPT
SCHEMBL1520186 0.81 KEAP1 (0.68) KEAP1NFE2L2CA2MAPTUTS2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 US disclosed
CN-116568677-A piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers 探戈医药股份有限公司 2023-08-08 CN disclosed
EP-0375451-A2 Compounds having a renin-inhibiting activity BEECHAM GROUP PLC (GB) 1990-06-27 EP disclosed
EP-0350163-A2 Renin inhibitory peptides BEECHAM GROUP PLC (GB) 1990-01-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228478-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 KEAP1 1708/4885NFE2L2 3140/4885CYP2A6 105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.